Curanex Pharmaceuticals Inc
CURX evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $7.1M
- Lead Asset:
- Phyto-N (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CURX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CURX
Curanex Pharmaceuticals Inc (CURX) is a pre-revenue, clinical-stage biopharmaceutical company developing botanical-based drug candidates targeting inflammatory and metabolic conditions, with a lead IND submission planned for ulcerative colitis.
Key risk: Cash runway insufficient for clinical trials
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$7.1M
Cash Runway
—
Lead Asset
Phyto-N (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc (CURX) is a pre-revenue, clinical-stage biopharmaceutical company developing botanical-based drug candidates targeting inflammatory and metabolic conditions, with a lead IND submission planned for ulcerative colitis.
- Has not generated any revenue since inception and has accumulated deficits of $11.3 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Cash and cash equivalents totaled $2.9 million as of June 30, 2026, with net loss of $3.3 million for the six months ended same date [sec].
- R&D expenses for the six months ended June 30, 2026 were $4,849,879, focused on IND-enabling studies for ulcerative colitis and cancer cachexia [sec_mda · as of 2026-08-14].
- Targets an IND submission for ulcerative colitis in Q4 2026, followed by a Phase I trial, but notes that clinical trial activities require substantial capital not yet secured [sec_mda · as of 2026-08-14].
- Qualifies as an emerging growth company and smaller reporting company, allowing scaled disclosures and delayed adoption of new accounting standards [sec · filed 2025-07-18].
What works
- Management intends to pursue non-dilutive funding opportunities such as research grants and contracts to support early-stage research [sec_mda · as of 2026-03-30].
- Awards under the 2026 Plan are settled in shares, conserving cash resources as the company works toward its IND submission [sec_mda · as of 2026-08-14].
What to weigh
- The company has no revenue, an accumulated deficit of $11.3 million, and relies on external financing to continue operations [sec].
- Clinical trial activities require substantial capital that has not yet been secured; failure to raise additional capital would require delaying or reducing development programs [sec_mda · as of 2026-08-14].
- Cash used in operating activities is expected to increase substantially as prepaid R&D balances are consumed, putting pressure on the already limited cash runway [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Curanex has not generated any revenue since inception and has an accumulated deficit of $11.3 million as of June 30, 2026.
“We have not generated any revenue since inception and have incurred recurring net losses and negative cash flows from operations. For the six months ended June 30, 2026, we incurred a net loss of $6,441,198 and used cash in operating activities of $2,034,671. As of June 30, 2026, we had cash and cash equivalents of $2,938,463 and an accumulated deficit of $11,288,753.”
SEC MD&A · August 14, 2026
Curanex targets an IND submission for ulcerative colitis in Q4 2026, but lacks sufficient capital for clinical trials.
“We further expect our research and development expenditures to increase in connection with our targeted Investigational New Drug application submission in the fourth quarter of 2026 and the initiation of a Phase I clinical trial thereafter. Clinical trial activities require substantial capital that we have not yet secured.”
SEC MD&A · August 14, 2026
Failure to raise capital would require delaying or eliminating development programs.
“If we are unable to raise additional capital when needed, we would be required to delay, reduce or eliminate certain of our development programs.”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Cash runway insufficient for clinical trials — With only $2.9M cash as of June 30, 2026, and no revenue, the company cannot fund the planned Phase I trial without new financing [sec].
- Reliance on future capital raises — The company's going concern qualification and need for external capital create dilution risk if equity is issued or restrictive covenants if debt is used [sec_mda · as of 2026-08-14].
- Pre-revenue and early-stage pipeline — No approved products or clinical trials; all programs are at the IND preparation stage, creating substantial development and regulatory uncertainty [sec_mda · as of 2026-08-14].
What to watch
- Outcome of IND submission for ulcerative colitis (targeted Q4 2026) [sec_mda · as of 2026-08-14].
- Ability to secure grant, contract, or equity financing given the cash position of $2.9M as of June 30, 2026 [sec].
- Potential appointment of a CEO with public R&D company experience and any additional regulatory advances related to botanical drug designation.
- Updates on the planned Phase I clinical trial initiation and any clinical data from other ongoing IND-enabling studies [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated September 12, 2026 · How we verify sources →
Run Curanex Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Curanex Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 0.0
- Shares short
- 137,290
- Daily short volume (Jun 16, 2026)
- 25.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CURX short interestFrequently asked questions
What is the AI investment thesis for Curanex Pharmaceuticals Inc?
Curanex Pharmaceuticals Inc (CURX) is a pre-revenue, clinical-stage biopharmaceutical company developing botanical-based drug candidates targeting inflammatory and metabolic conditions, with a lead IND submission planned for ulcerative colitis.
What is Curanex Pharmaceuticals Inc's lead drug candidate?
Curanex Pharmaceuticals Inc's most advanced tracked candidate is Phyto-N (Preclinical) for gout.
Who is the CEO of Curanex Pharmaceuticals Inc?
Mr. Jun Liu is the chief executive officer of Curanex Pharmaceuticals Inc (CURX).
Where is Curanex Pharmaceuticals Inc headquartered?
Curanex Pharmaceuticals Inc (CURX) is headquartered in Jericho, NY, United States.
What therapeutic areas does Curanex Pharmaceuticals Inc focus on?
Curanex Pharmaceuticals Inc develops therapies across Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.